One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction

Kang Yin Chen, Seung-Woon Rha, Lin Wang, Yong Jian Li, Guang Ping Li, Cheol Ung Choi, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, Myung Ho Jeong, Young Keun Ahn, Taek Jong Hong, Young Jo Kim, Shung Chull Chae, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho Bae, Dong Hoon Choi & 9 others Yang Soo Jang, In Ho Chae, Hyo Soo Kim, Chong Jin Kim, Jung Han Yoon, Tae Hoon Ahn, Wook Sung Chung, Ki Bae Seung, Seung Jung Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).

Methods: This study includes 2911 AMI patients treated with SES (n= 1264) or EES (n= 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity scorematching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomeswere compared between the two propensity scorematched groups.

Results: Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P= 1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P= 0.619), target lesion revascularization (1.4% vs. 1.6%, P= 0.737), target lesion failure (7.0% vs. 7.3%, P= 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P= 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P= 0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group.

Conclusions: The present propensity scorematched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalInternational Journal of Cardiology
Volume176
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Sirolimus
Stents
Myocardial Infarction
Propensity Score
Everolimus
Registries
Drug-Eluting Stents
Korea
Paclitaxel
Thrombosis
Research Design

Cite this

One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction. / Chen, Kang Yin; Rha, Seung-Woon; Wang, Lin; Li, Yong Jian; Li, Guang Ping; Choi, Cheol Ung; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo; Jeong, Myung Ho; Ahn, Young Keun; Hong, Taek Jong; Kim, Young Jo; Chae, Shung Chull; Hur, Seung Ho; Seong, In Whan; Chae, Jei Keon; Cho, Myeong Chan; Bae, Jang Ho; Choi, Dong Hoon; Jang, Yang Soo; Chae, In Ho; Kim, Hyo Soo; Kim, Chong Jin; Yoon, Jung Han; Ahn, Tae Hoon; Chung, Wook Sung; Seung, Ki Bae; Park, Seung Jung.

In: International Journal of Cardiology, Vol. 176, No. 3, 01.01.2014, p. 583-588.

Research output: Contribution to journalArticle

Chen, KY, Rha, S-W, Wang, L, Li, YJ, Li, GP, Choi, CU, Park, CG, Seo, HS, Oh, DJ, Jeong, MH, Ahn, YK, Hong, TJ, Kim, YJ, Chae, SC, Hur, SH, Seong, IW, Chae, JK, Cho, MC, Bae, JH, Choi, DH, Jang, YS, Chae, IH, Kim, HS, Kim, CJ, Yoon, JH, Ahn, TH, Chung, WS, Seung, KB & Park, SJ 2014, 'One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction', International Journal of Cardiology, vol. 176, no. 3, pp. 583-588. https://doi.org/10.1016/j.ijcard.2014.08.049
Chen, Kang Yin ; Rha, Seung-Woon ; Wang, Lin ; Li, Yong Jian ; Li, Guang Ping ; Choi, Cheol Ung ; Park, Chang Gyu ; Seo, Hong Seog ; Oh, Dong Joo ; Jeong, Myung Ho ; Ahn, Young Keun ; Hong, Taek Jong ; Kim, Young Jo ; Chae, Shung Chull ; Hur, Seung Ho ; Seong, In Whan ; Chae, Jei Keon ; Cho, Myeong Chan ; Bae, Jang Ho ; Choi, Dong Hoon ; Jang, Yang Soo ; Chae, In Ho ; Kim, Hyo Soo ; Kim, Chong Jin ; Yoon, Jung Han ; Ahn, Tae Hoon ; Chung, Wook Sung ; Seung, Ki Bae ; Park, Seung Jung. / One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction. In: International Journal of Cardiology. 2014 ; Vol. 176, No. 3. pp. 583-588.
@article{682ee20ca7c144dda6d7a376e56979a4,
title = "One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction",
abstract = "Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).Methods: This study includes 2911 AMI patients treated with SES (n= 1264) or EES (n= 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity scorematching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomeswere compared between the two propensity scorematched groups.Results: Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8{\%} vs. 4.8{\%}, P= 1.000), recurrent myocardial infarction (1.4{\%} vs. 1.7{\%}, P= 0.619), target lesion revascularization (1.4{\%} vs. 1.6{\%}, P= 0.737), target lesion failure (7.0{\%} vs. 7.3{\%}, P= 0.752), and probable or definite stent thrombosis (0.5{\%} vs. 0.9{\%}, P= 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9{\%} vs. 3.0{\%}, P= 0.087) and a lower rate of total major adverse cardiac events (9.3{\%} vs. 11.9{\%}, P = 0.034) in the EES group.Conclusions: The present propensity scorematched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.",
keywords = "Acute myocardial infarction, Everolimus-eluting stents, Percutaneous coronary intervention, Sirolimus-eluting stents",
author = "Chen, {Kang Yin} and Seung-Woon Rha and Lin Wang and Li, {Yong Jian} and Li, {Guang Ping} and Choi, {Cheol Ung} and Park, {Chang Gyu} and Seo, {Hong Seog} and Oh, {Dong Joo} and Jeong, {Myung Ho} and Ahn, {Young Keun} and Hong, {Taek Jong} and Kim, {Young Jo} and Chae, {Shung Chull} and Hur, {Seung Ho} and Seong, {In Whan} and Chae, {Jei Keon} and Cho, {Myeong Chan} and Bae, {Jang Ho} and Choi, {Dong Hoon} and Jang, {Yang Soo} and Chae, {In Ho} and Kim, {Hyo Soo} and Kim, {Chong Jin} and Yoon, {Jung Han} and Ahn, {Tae Hoon} and Chung, {Wook Sung} and Seung, {Ki Bae} and Park, {Seung Jung}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ijcard.2014.08.049",
language = "English",
volume = "176",
pages = "583--588",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - One-year clinical outcomes of everolimus-versus sirolimus-eluting stents in patients with acute myocardial infarction

AU - Chen, Kang Yin

AU - Rha, Seung-Woon

AU - Wang, Lin

AU - Li, Yong Jian

AU - Li, Guang Ping

AU - Choi, Cheol Ung

AU - Park, Chang Gyu

AU - Seo, Hong Seog

AU - Oh, Dong Joo

AU - Jeong, Myung Ho

AU - Ahn, Young Keun

AU - Hong, Taek Jong

AU - Kim, Young Jo

AU - Chae, Shung Chull

AU - Hur, Seung Ho

AU - Seong, In Whan

AU - Chae, Jei Keon

AU - Cho, Myeong Chan

AU - Bae, Jang Ho

AU - Choi, Dong Hoon

AU - Jang, Yang Soo

AU - Chae, In Ho

AU - Kim, Hyo Soo

AU - Kim, Chong Jin

AU - Yoon, Jung Han

AU - Ahn, Tae Hoon

AU - Chung, Wook Sung

AU - Seung, Ki Bae

AU - Park, Seung Jung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).Methods: This study includes 2911 AMI patients treated with SES (n= 1264) or EES (n= 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity scorematching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomeswere compared between the two propensity scorematched groups.Results: Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P= 1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P= 0.619), target lesion revascularization (1.4% vs. 1.6%, P= 0.737), target lesion failure (7.0% vs. 7.3%, P= 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P= 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P= 0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group.Conclusions: The present propensity scorematched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.

AB - Background: In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).Methods: This study includes 2911 AMI patients treated with SES (n= 1264) or EES (n= 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity scorematching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomeswere compared between the two propensity scorematched groups.Results: Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P= 1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P= 0.619), target lesion revascularization (1.4% vs. 1.6%, P= 0.737), target lesion failure (7.0% vs. 7.3%, P= 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P= 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P= 0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group.Conclusions: The present propensity scorematched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.

KW - Acute myocardial infarction

KW - Everolimus-eluting stents

KW - Percutaneous coronary intervention

KW - Sirolimus-eluting stents

UR - http://www.scopus.com/inward/record.url?scp=84908151173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908151173&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.08.049

DO - 10.1016/j.ijcard.2014.08.049

M3 - Article

VL - 176

SP - 583

EP - 588

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -